Riskpilot← Back to searchSign inGet full accessAktiebolaget Biox
ABActiveOrg 5560775891Dybecksgatan 10Wholesale of pharmaceutical and medical goods · NACE 4646Est. 19610 employees
Revenue 2024
SEK -1
0% vs 2023
EBITDA margin
7157000.0%
+19% vs 2023
Equity ratio
94.1%
Financial strength
Net profit 2024
SEK -963
+99% vs 2023
| Revenue | SEK -1 | +0% |
| EBITDA | SEK -72K | +19% |
| Net profit | SEK -963 | +99% |
| Total assets | SEK 3,2M | +0% |
| Equity | SEK 3M | +0% |
| Employees | 0 | — |
Legal name
Aktiebolaget Biox
Org number
5560775891
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
7 mars 1961
Share capital
SEK 200 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av Edebo, Anders Felix Edebo, Cecilia Margareta Edebo, Lars Bennet
Company purpose
Bolaget skall driva utveckling och försäljning av medicinska och bioteknisk utrustning samt utöva medicinsk och bioteknisk konsultverksamhet ävensom idka därmed förenlig verksamhet.
Address
Dybecksgatan 10
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | −0 | −0 | −0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −141 | −71 | −68 | −88 | −72 |
| Depreciation & amort. | −0 | −0 | −24 | — | — |
| EBIT | −141 | −71 | −92 | −88 | −72 |
| Net financials | — | 842 | 0 | 1 | 71 |
| Profit before tax | −141 | 771 | −92 | −87 | −1 |
| Tax | −0 | −0 | — | — | — |
| Net profit | −141 | 771 | −92 | −87 | −1 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 2 494 | 3 296 | 3 231 | 3 205 | 3 212 |
| Equity | 2 432 | 3 203 | 3 111 | 3 024 | 3 023 |
| Long-term debt | 31 | 63 | 90 | 150 | 159 |
| Short-term debt | 30 | 30 | 30 | 30 | 30 |
| Total debt | 61 | 93 | 120 | 180 | 189 |
EBITDA margin
-7157000.0%
This company
15.8%
Market median
-45297568% vs market
20202024
Equity ratio
94.1%
This company
38.2%
Market median
+146% vs market
20202024
Return on equity
-0.0%
This company
18.4%
Market median
-100% vs market
20202024
Net profit margin
-96300.0%
This company
8.1%
Market median
-1188989% vs market
20202024
Asset turnover
-0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.06×
This company
0.62×
Market median
+90% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
AF Chief Executive Officer | Chief Executive Officer | 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2021 | |
| Deputy Board Member | 2021 | |
| Chairman | 2021 | |
| Former (1) | ||
| Deputy Board Member | 2021 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Aktiebolaget Biox also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anders Felix Edebo | Chief Executive Officer | 0 companies |
| Cecilia Margareta Edebo | Board of Directors | 0 companies |
| Claes Fredrik Edebo | Deputy Board Member | 0 companies |
| Margareta Cecilia Ekroth Edebo | Deputy Board Member | 0 companies |
| Lars Bennet Edebo | Chairman | 0 companies |